Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA publishes food registry guidance

This article was originally published in The Tan Sheet

Executive Summary

The agency solicits public comment on a draft guidance regarding the reportable food registry, which is slated for implementation Sept. 8. Under RFR, responsible parties - including manufacturers, processors and packagers - will need to alert the agency through its main Web portal that an adulterated food product has the potential to "cause serious adverse health consequences or death to humans," FDA said June 11. The comment period ends June 26. The guidance includes information on when RFR reports must be filed and the information they must include. As specified in the FDA Amendments Act of 2007, RFR reporting requirements exclude infant formula and dietary supplements (1"The Tan Sheet" Sept. 24, 2007)

You may also be interested in...



FDA food registry now taking reports

The agency requires food facilities to submit to its Web-based reportable food registry cases where a product has a "reasonable probability" of causing severe health problems or death. RFR, which launched Sept. 8 at 1http://rfr.fda.gov/, does not apply to dietary supplements or infant formulas (2"The Tan Sheet" June 29, 2009, In Brief). Michael Taylor, senior advisor to the FDA commissioner, said real-time reporting "enhances FDA's ability to act quickly to prevent food-borne illness." Rep. John Dingell, D-Mich., called RFR "an important first step," but said Congress must still pass food safety legislation. Food firms must comply with RFR requirements immediately, but FDA's guidance says the agency may exercise enforcement discretion until Dec. 8 for parties that make "a reasonable effort to comply.

FDA Reauthorization Steers Clear Of Agency’s OTC Authority, DSHEA, AER Law

The FDA reauthorization bill Congress has passed does not rock the boat on FDA's current authority over either over-the-counter switches or dietary supplements

Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions

Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.

Topics

UsernamePublicRestriction

Register

PS103064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel